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Abstract 
BRM (BRAHMA) is a core, SWI2/SNF2-type ATPase subunit of SWI/SNF chromatin-remodelling complex (CRC) involved 
in various important regulatory processes including development. Mutations in SMARCA2, a BRM-encoding gene 
as well as overexpression or epigenetic silencing were found in various human diseases including cancer. Missense 
mutations in SMARCA2 gene were recently connected with occurrence of Nicolaides–Baraitser genetics syndrome. 
By contrast, SMARCA2 duplication rather than mutations is characteristic for Coffin–Siris syndrome. It is believed that 
BRM usually acts as a tumour suppressor or a tumour susceptibility gene. However, other studies provided evidence 
that BRM function may differ depending on the cancer type and the disease stage, where BRM may play a role in the 
disease progression. The existence of alternative splicing forms of SMARCA2 gene, leading to appearance of truncated 
functional, loss of function or gain-of-function forms of BRM protein suggest a far more complicated mode of BRM-
containing SWI/SNF CRCs actions. Therefore, the summary of recent knowledge regarding BRM alteration in various 
types of cancer and highlighting of differences and commonalities between BRM and BRG1, another SWI2/SNF2 type 
ATPase, will lead to better understanding of SWI/SNF CRCs function in cancer development/progression. BRM has 
been recently proposed as an attractive target for various anticancer therapies including the use of small molecule 
inhibitors, synthetic lethality induction or proteolysis-targeting chimera (PROTAC). However, such attempts have some 
limitations and may lead to severe side effects given the homology of BRM ATPase domain to other ATPases, as well as 
due to the tissue-specific appearance of BRM- and BRG1-containing SWI/SNF CRC classes. Thus, a better insight into 
BRM-containing SWI/SNF CRCs function in human tissues and cancers is clearly required to provide a solid basis for 
establishment of new safe anticancer therapies.
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Main text
Background
The genomic DNA in eukaryotic cells nuclei is pack-
aged together with histone proteins into a complex 
called chromatin, enabling the storage of a relatively 
large amount of DNA in a very compacted form. How-
ever, the structure of chromatin restricts the contact 
between DNA and various protein (e.g. activators, 
repressors, modifying enzymes) or non-protein (e.g. 
enhancers, silencers) regulatory elements. Therefore, 
chromatin is a target for various modifications includ-
ing chromatin remodelling, which controls the access to 
DNA sequences. The process is executed by multiprotein 
chromatin-remodelling complexes (CRCs), which utilise 
energy from ATP hydrolysis [1].
BRM ATPase, the SWI2/SNF2‑type core subunit of SWI/SNF 
chromatin‑remodelling complexes
One of the best-characterised chromatin-remodelling 
complexes (CRCs) are SWI/SNF CRCs. Originally, the 
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SWI/SNF CRC was described in baker’s yeast, where it 
affected mating-type switch (SWI) [2] and sucrose fer-
mentation (SNF—sucrose non-fermenting) [3, 4]. The 
SWI/SNF complexes were thus named for these phe-
notypic alterations [5]. Homologues of yeast SWI/SNF 
CRCs’ subunits were subsequently found in other organ-
isms including humans [6], proving that they are highly 
evolutionary conserved among all Eukaryotes [1]. The 
SWI/SNF CRCs are involved in the regulation of various 
crucial cellular processes such as the cell cycle, cell mor-
phology and adhesion, apoptosis, signal transduction, 
DNA repair and stress response, which are frequently 
and significantly altered in cancer [7–10].
SWI/SNF CRCs are multiprotein complexes, built from 
10 to 15 subunits. Depending on the subunit composi-
tion, several classes of SWI/SNF CRCs may exist in the 
cell simultaneously [11]. The SWI/SNF subunit composi-
tion and activity is cell/tissue-specific [12].
It was believed that the core complexes of all types of 
SWI/SNF CRCs consist of four core subunits—one of two 
ATPase subunits: BRM (encoded by SMARCA2 gene) or 
BRG1 (encoded by SMARCA4 gene), BAF155 (encoded 
by SMARCC1 gene), BAF170 (encoded by SMARCC2 
gene) and INI1 (SNF5 or BAF47, encoded by SMARCB1 
gene) [7, 13]. Together with the core complex, non-core 
subunits are present in the SWI/SNF CRCs. The number 
of non-core subunits may differ and their composition 
influences activity of the whole complex.
Recent studies by several research groups indicated the 
existence of non-canonical SWI/SNF CRC classes lacking 
some core (i.e. INI1) and non-core subunits [14, 15]. Fur-
thermore, the presence of non-canonical SWI/SNF com-
plexes was also shown using mouse models [16].
The SWI/SNF CRCs utilise energy from ATP hydroly-
sis to disrupt contact between the DNA and histones, 
leading to nucleosome disassembly [17, 18]. They control 
gene expression by moving or removing nucleosomes 
covering binding sites for transcription factors [19] or 
stabilising nucleosome positions. The activity of SWI/
SNF CRCs requires recruitment to the DNA by tran-
scription regulators and other factors [20]. The action 
of SWI/SNF CRCs alters upon interactions with vari-
ous proteins such as hormone receptors [21], acetylases/
deacetylases, etc. and depends on the modification of its 
subunits by, e.g. acetylation, as has been observed for 
the BRM ATPase subunit. A comprehensive summary of 
SWI/SNF CRCs’ action was provided by Sarnowska et al. 
[19].
BRM and BRG1 ATPase subunits are critical for the 
SWI/SNF activity. Both of them belong to the SWI2/
SNF2 family, share about 75% structural homology 
and share similar ATPase and helicase activities [6], 
although their function is not identical. In humans, 
BRG1 ATPase may be present in both SWI/SNF CRC 
classes—BAF (BRM or BRG1-associated factors) and 
PBAF (polybromo BRG1-associated factors), while 
BRM has been found in BAF class of SWI/SNF com-
plexes only and is the so-called signature subunit of 
this complex class. BRM has lower ATPase activity than 
BRG1 [22, 23], therefore, its less important role was 
postulated.
This hypothesis has been supported by mouse models 
where Brm-knockout (Brm−/−) mice lived until adult-
hood and developed tumours while  Brg1−/− null mutants 
caused embryonic lethality [24]. It has also been shown 
that Brm controls cellular proliferation by regulation 
of the cell cycle [25]. The mouse model study revealed 
that both homozygous and heterozygous loss of Brm 
resulted in an increased risk of tumour development, 
when exposed to carcinogens [22]. Therefore, it is pro-
posed that Brm rather acts as a cancer susceptibility than 
a tumour suppressor gene [26]. The importance of Brm 
in mice has been shown by several additional studies, i.e. 
using conditional knockout of both genes encoding BRM 
and BRG1 ATPases in heart. In this case, the concomi-
tant depletion of Brm and Brg1 resulted in severe cardiac 
dysfunction associated with glycogen accumulation and 
mitochondrial defects, eventually leading to death [27]. 
Moreover, functional Brm protein is crucial for the ini-
tiation of regeneration phase after liver injury and domi-
nates during the late injury phase on Brg1 function [28].
The double-knockout mice Brm−/−/Brg1−/− exhibited 
an unexpected ability to overcome loss of both ATPases. 
In fact, Brm−/−/Brg1−/− mice restored Brm expression 
via an alternative splicing strategy which resulted in pro-
duction of truncated but functional Brm protein [29]. 
This study, together with the existence of alternative 
splicing variants of SMARCA2 gene [30], indicate that 
the role of BRM may be more complicated than so far 
reported. It may be due to the fact that several different 
forms of BRM protein may exist in the cell.
The loss of human BRM or BRG1 consequently leads to 
the modified expression of genes that are significant for 
tumour development, e.g. genes encoding tumour sup-
pressors. Many of them control cellular processes such 
as metabolism (including drug metabolism), DNA repair, 
differentiation, adhesion and apoptosis, and are involved 
in angiogenesis, progression or metastasis of cancer [31]. 
Recent studies on ovarian cancer revealed that BRG1 
and BRM ATPases are mutually exclusive as their paral-
lel inactivation leads to synthetic lethality [32], although 
other reports indicated the survival of cells with deple-
tion of both ATPases [31]. One possible explanation of 
this apparent discrepancy may be the existence of shorter, 
truncated but functional versions of BRM protein which 
are simply not recognised by the anti-BRM antibody.
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In human heterozygous missense, mutations in BRM-
encoding SMARCA2 gene were identified in patients with 
Coffin–Siris (CSS) and Nicolaides–Baraitser (NCBRS) 
syndromes [33]. Although the last study performed on a 
large cohort of CSS patients proved that they carry the 
missense mutation in SMARCA4 (BRG1 encoding gene) 
gene but not in BRM-encoding SMARCA2 gene. In some 
CSS patients, duplication of the SMARCA2 gene was 
detected [34]. On the other hand, missense mutations in 
SMARCA2 were detected in NCBRS patients [35]. More-
over, one individual with SMARCA2 mutation was previ-
ously diagnosed with CSS and after was reclassified for 
NCBRS [36, 37]. This collectively suggests that missense 
mutations in SMARCA4 and SMARCA2 may cause dif-
ferent developmental disabilities, although both CSS and 
NCBRS syndromes share some similar developmental 
dysfunctions and their distinction is based mostly on foot 
and hand features [35] (Fig. 1).
The occurrence of developmental alterations in CSS 
and NCBRS could be in contradiction with mouse mod-
els, where heterozygous loss in the Brm-encoding gene 
has no developmental effects. Although, in CSS the dupli-
cation of SMARCA2 gene may lead to overexpression of 
BRM protein and as a consequence altered SWI/SNF 
stoichiometry caused by the pathological competition of 
BRM with BRG1 ATPase. In NCBRS, the missense muta-
tions in SMARCA2 may result in BRM gain-of-function 
or loss of function, i.e. by fast protein degradation. The 
exact role of SMARCA2 missense mutations or duplica-
tion during development is still unclear; however, the 
SMARCA2 polymorphisms may lead to higher cancer 
risk, suggesting the role of human BRM as a cancer sus-
ceptibility gene, similarly to mice [38].
It is also important to note that the classes of human 
SWI/SNF CRCs containing BRG1 or BRM subunits may 
regulate different promoters and sometimes they even 
differentially regulate transcription of the same genes 
[19]. This could be based on the differences in transcrip-
tion factor recruitment, subunit composition and the 
occurrence of differential modifications of SWI/SNF sub-
units [23]. The picture of BRM/BRG1 interdependence is 
broadened by the in-depth, high throughput study based 
on ChIPseq and RNAseq analysis of BRM or BRG1-
depleted HepG2 cell line. This study revealed that deple-
tion of one ATPase subunit frequently leads to decreased 
abundance of the remaining subunit. Additionally, on 
numerous genes, the remaining subunit is either retained 
or gained [39]. All the above data suggest that in cancer, 
both ATPases have similar functions and could be par-
tially redundant.
Mechanism of action
BRM-containing SWI/SNF CRCs regulate expression 
of a large number of genes involved in carcinogenesis 
including (i) epithelial–mesenchymal transition genes, 
e.g. CDH2 (N-cadherin) and SNAI1; (ii) cell cycle genes, 
e.g. CCND1 (cyclin D1), CCNE2 (cyclin E2), CDK4 and 
CDK6 (cyclin kinases), (iii) metabolic genes, e.g. GAPDH, 
ALDOA and LDHA; (iv) cancer suppressor genes and 
oncogenes, e.g. BRCA1, PTEN, AKT1, HRAS and KRAS. 
Importantly, BRM also regulates expression of self-
encoding SMARCA2 gene and other SWI/SNF subunits 
[40].
BRM directly interacts with the retinoblastoma pro-
tein (Rb) and its family members [7, 41, 42]. Through this 
interaction, BRM influences cell cycle, causing repression 
Fig. 1 The phenotypic differences and commonalities between NCBRS and CSS. The red lines correspond to mutation sites in SMARCA2 and 
SMARCA4 genes according to [136]
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of E2 promoter binding factor (E2F) family transcription 
factors [43]. Cells lacking BRM cannot enter the  G1/S 
phase resulting in growth arrest [44] (Fig. 2). BRM func-
tion in the cell cycle is probably dependent on the phos-
phorylation of BRM by cyclin E/CDK2 complex causing 
dissociation of Rb from ATPase [45], and leading to cell 
cycle progression [46]. However, some data suggest that 
BRG1 has a more significant role in cell cycle control 
than BRM and, therefore, the specific role of BRM in Rb-
mediated cell cycle inhibition remains elusive [47].
The link between SWI/SNF CRCs and TP53, a com-
monly mutated oncogene, is also known [48]; however, 
the particular role of BRM ATPase in this dependency is 
still unclear. Xu and colleagues demonstrated that BRM 
and BRG1 affect TP53-dependent p21 transcription dif-
ferently. BRG1 knock-down handicaps TP53 binding to 
p21 promoter although BRM has ability to replace BRG1 
in TP53 regulation [49].
Interestingly, mice lacking Brm did not present path-
ological Tp53 mutations in tumours, although such 
mutations were accumulated in Brm-positive tumours, 
suggesting that loss of Brm would restrain selection of 
Tp53-mutated variant in tumour evolution. Collectively, 
this observation strongly suggests the existence of vari-
ous ways of tumour evolution and development [47].
Some data indicate SWI/SNF participation in DNA 
damage response. BRM is involved in non-homologous 
end-joining (NHEJ) DNA repair, although its activity in 
this process depends on SWI/SNF complex composition 
[50]. BRM recruitment to double-strand breaks depends 
on, i.e. histone 2B phosphorylation on Ser36 which pro-
motes BRM involvement in this process. Ribeiro-Silva 
and colleagues [51] observed that BRM is required for 
correct recruitment of the transcription factor II H 
(TFIIH) to the DNA damage site and facilitates DNA 
nucleotide excision repair pathway. Moreover, the SWI/
SNF CRC also participates in DNA damage repair by 
interactions with BRCA1, indicating its important role in 
homologous recombination [52] (Fig. 2).
BRM also plays an important role in regulation of 
alternative splicing via interaction with spliceosome 
components. BRM overexpression favours inclusion of 
alternative exons [53], which is consistent with the obser-
vation that BRM is present not only on promoter regions, 
but also in the gene body [39] (Fig. 2).
Sakurai et  al. [54] and Kobayashi et  al. [55] demon-
strated that BRM participates in the miRNA containing 
axis, particularly miR-199 and transcriptionally regulates 
the miR-302a-3p expression [56]. BRM is also involved 
in JAK2/STAT3 pathway, causing its activation [57]. 
The SWI/SNF BRM-containing CRC acts in the con-
trol of hormonal signalling pathways and participates in 
hormonal crosstalk [19]. In particular, BRM is required 
for proliferation of androgen-dependent prostate can-
cer [58] and regulates androgen receptor (AR) target 
genes expression [59]. Additionally, in cooperation with 
Fig. 2 BRM-involving cellular processes. BRM protein is involved in a variety of cellular processes both in healthy/normal and cancerous cells; for 
example, gene expression control, alternative splicing, cell cycle control, participating in hormonal response and miRNA transcription and signalling. 
In pathological situations, in cancer cells, BRM can leave the cell nuclei and migrate to cytoplasm or cell membrane, although specific effects of 
BRM in these locations are unknown
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Table 1 The known BRM interactors and processes involving BRM
Lp. Full name Abbreviations Gene name(s) Function; biological process Refs.
Transcription factors
 1 Androgen receptor AR AR, DHTR, NR3C4 Transcription regulation, 
hormone receptor
[137–139]
 2 Breast cancer type 1 suscepti-
bility protein; breast cancer 
1, early onset
BRCA1 BRCA1, RNF53 DNA repair, transcription regu-
lation, metabolism
[140–142]
 3 CCAAT/enhancer-binding 
protein alpha
C/EBP alpha, CEBPA CEBPA, CEBP Transcription regulation, DNA-
binding
[143]
 4 Chromobox protein homolog 5 CBX5, HP1 alpha CBX5, HP1A Transcription regulation, chro-
matin organisation
[144, 145]
 5 Endothelial PAS domain- 
containing protein 1
EPAS-1, bHLHe73, HLF, HIF-
2-alpha
EPAS1, BHLHE73, HIF2A, MOP2, 
PASD2
Transcription factor, hypoxia 
induced regulator of oxygen 
related genes
[146]
 6 EP300-interacting inhibitor of 
differentiation 1
EP300, EID-1 EID1 C15orf3, CRI1, RBP21, 
PNAS-22, PTD014
Transcription regulation, cell 
cycle, differentiation
[147]
 7 Oestrogen receptor ER ESR1, ESR, NR3A1 Transcription regulation, 
hormone receptor
[148]
 8 Histone H2A deubiquitinase 
MYSM1
2A-DUB, MYSM1 MYSM1, KIAA1915 Transcription regulation, chro-
matin regulator
[149]
 9 Histone deacetylase 1 HD1, HDAC1 HDAC1, RPD3L1 Histone deacetylase, transcrip-
tion regulation
[22, 150]
 10 Histone deacetylase 2 HD2, HDAC2 HDAC2 Histone deacetylase, transcrip-
tion regulation
[22, 150]
 11 Histone-lysine N-methyltrans-
ferase EZH2
EXH2, ENX-1 EZH2, KMT6 PRC2 main subunit, transcrip-
tion regulation, chromatin 
regulation
[151]
 12 Homeobox protein CDX-2 CDX-2 CDX2, CDX3 Transcription regulation, devel-
opmental protein
[152]
 13 Hypoxia-inducible factor 
1-alpha
HIF-1-alpha, bHLHe78 HIF1A, BHLHE78, MOP1, PASD8 Transcription factor, master 
regulator of the adaptive 
response to hypoxia
[153]
 14 Myc proto-oncogene protein c-Myc, bHLHe39 MYC, BHLHE39 Transcription factor recognis-
ing sequence 5′-CAC[GA]
TG-3′
[154]
 15 Nuclear receptor corepressor 1 NCOR1 NCOR1, KIAA1047 Transcription regulation [155]
 16 Paired amphipathic helix 
protein Sin3a
SIN3A SIN3A Transcription regulation [22, 150, 156]
 17 Polycomb protein EED EED, hEED, WAIT-1 WAIT-1 Transcription regulation, chro-
matin regulation
[157]
 18 Signal transducer and activator 
of transcription 1-alpha/beta
– STAT1 Transcription factor [147]
 19 Transcription activator MYB c-Myb MYB Transcription regulation [158]
 20 Transcription factor AP-1 c-Jun, AP1, p39 JUN Transcription regulation [159]
 21 Transcription factor SOX-2 SOX2 SOX2 Transcription regulation [160, 161]
 22 Transcription initiation factor 
TFIID subunit 1
p250, TAF(II)250, TAFII-250, 
TAFII250
TAF1 Transcription regulation, cell 
cycle
[150]
Others
 23 DNA-directed RNA polymerase 
II subunit RPB1
POLR2A, RNAPII RNAPII, POLR2 RNA polymerase, transcription [53, 162]
 24 Protein arginine N-methyl-
transferase 5
PRMT5, SKB1 homolog, SKB1Hs PRMT5, HRMT1L5, IBP72, JBP1, 
SKB1
Arginine methyltransferase [156]
 25 Proto-oncogene c-Fos c-Fos FOS, G0S7 DNA-binding [159]
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prohibitin, BRG1 or BRM ATPases are crucial for oes-
trogen antagonist-mediated breast cancer growth sup-
pression [60]. The known BRM interactors and processes 
involving BRM are summarised in Table  1. The large 
interaction network of BRM suggests a strong potential 
impact of any BRM impairment on numerous regulatory 
processes.
BRM aberrations in human cancer
The importance of an altered level and/or aberrant func-
tion of BRM in various cancers is not fully understood, 
although there is abundant evidence indicating the cru-
cial BRM role in carcinogenesis. About 15% of all can-
cers display numerous aberrations in BRM abundance 
or impairment, that may lead to cancer development or 
progression (Fig. 3).
Rhabdoid tumours
Malignant rhabdoid tumour (MRT) is an extremely 
aggressive type of cancer that affects mostly children. The 
mutations in SMARCB1 an INI1/SNF5/BAF47-encoding 
gene were found in this type of cancer, suggesting the 
mutation in a gene encoding core SNF5-type subunit 
of SWI/SNF CRCs as a driving mutation for this cancer 
type [61, 62]. This INI1 alteration was accompanied by 
BRM epigenetic silencing in about 70% of MRT cases. 
BRM was silenced by the HDAC-driven mechanism or by 
SMARCA2 promoter polymorphisms [53]. Interestingly, 
BRM expression was induced by INI1 re-expression and 
synthetic flavonoid treatment. BRM re-expression was 
necessary for flavonoid or INI1 re-expression induced 
growth inhibition of rhabdoid cell line [63].
Lung cancer
The downregulation of BRM is most frequently reported 
in lung cancer (LC) especially in non-small cell lung car-
cinoma (NSCLC). In case of the adenocarcinoma (AD), 
the amount of cases with BRM depletion is 6–17% [64, 
65], although in the group of poorly differentiated ADs 
the fraction of cases with BRM depletion reaches 92% 
Fig. 3 Schematic summary of BRM role in cancer development. ↑—upregulation; ↓—downregulation; TNBC triple-negative breast cancer, HCC 
hepatocellular carcinoma, UATC upper aerodigestive tract, SCCOHT small cell carcinoma of the ovary, hypercalcaemic type, OCCC ovarian clear 
cell carcinoma; OCC ovarian cell carcinoma, HNSCC head and neck squamous cell carcinoma, ACC adenoid cystic carcinoma; NSCLC non-small cell 
lung cancer; AD adenocarcinoma od the lung, LC large cell carcinoma of the lung; PL pleomorphic carcinoma of the lung; ccRCC clear cell renal cell 
carcinoma, NMSC non-melanoma skin cancer
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[64–66]. The highest downregulation of BRM protein 
was observed in the pleomorphic carcinoma of the lung 
(PL)—over 40% cases [66], and in the large cell carcinoma 
of the lung (LCCL)—33–50% cases [64, 66]. BRM stain-
ing is positive in lepidic growth components in LC and 
becomes significantly lower or negative in invasive parts 
[65, 66].
The BRM level in the primary NSCLC is associ-
ated with the survival rate. The overall survival for the 
group of patients with loss of nuclear BRM was signifi-
cantly lower comparing to patients with high BRM level. 
Additionally, a membrane form of BRM was observed 
in immunohistochemistry in some samples. In the case 
of AD, 5-year survival of patients with positive staining 
for the membrane BRM was significantly lower than in 
case of patients without the membrane BRM, suggest-
ing that the presence of the membrane BRM form may 
be a good prognostic marker [67]. However, the func-
tion of the membrane form of BRM remains unknown 
and there are no data regarding such localisation of other 
subunits of SWI/SNF CRCs. Intriguingly, loss of BRM 
and BRG1 in this type of cancer is correlated with loss of 
tumour cells’ ability to differentiate [31, 65]. A correlation 
between loss of BRG1 and BRM and epithelial–mesen-
chymal transition (EMT) in lung cancer was reported, 
especially in poorly differentiated ADs. Loss of BRM pro-
tein was more frequent in heavy smokers, supporting the 
hypothesis that BRM depletion enhances susceptibility 
to cancer induced by the carcinogen exposure [65, 68]. 
On the other hand, targeting BRM in the BRG1-deficient 
lung cancer (NSCLC) sensitised cancer cells (cell lines) to 
radiotherapy [69].
Renal cell carcinoma
SWI/SNF CRCs are aberrant in clear cell renal cell car-
cinoma (ccRCC), the most common type of renal cancer 
[70, 71]. The 3% of all ccRCC cases were BRM-negative. 
All BRM-negative cases were classified as poorly differ-
entiated grade 4 tumours [72]. It is also significant that 
loss of BRM was observed only in ccRCC, and not in 
other types of renal cancers like fumarate hydratase-defi-
cient RCC [73].
Interestingly, in the case of RCC, the same pattern 
as in lung cancer was observed—poorly differentiated 
tumours or poorly differentiated parts of tumours were 
lacking a BRM subunit, while more differentiated areas 
showed BRM expression [72, 74] suggesting that altera-
tions of SMARCA2 gene occur during de-differentiation 
of ccRCC. Thus, BRM loss may be specifically linked to 
the tumour aggressiveness. In BRM-deficient ccRCC 
tumours almost 90% cases displayed genetic alterations 
in the SMARCA2 gene, such as mutations, promoter 
methylation or chromosomal aberrations. Interestingly, 
the alterations were very rare in low-grade part of ana-
lysed tumours and in non-neoplastic tissue [74]. These 
observations strongly suggest that loss of BRM occurred 
during cancer progression.
Cancers of gastrointestinal tract
Loss of SWI/SNF subunits correlates with undifferenti-
ated tumour phenotypes in gastrointestinal tract (GI) 
cancers. Interestingly, in rare GI cancers, with rhabdoid 
features no concurrent loss of BRM and BRG1 ATPases 
was observed. On the other hand, concomitant inactiva-
tion of BRM and INI1/SNF5/BAF47 frequently lost in 
rhabdoid carcinomas was reported [75].
Inactivation of the BRM-encoding SMARCA2 gene by 
the presence of promoter indel polymorphisms correlates 
with higher risk of colorectal cancer [76]. These promoter 
indels increase risk of upper aerodigestive tract cancers 
(UATC) more than twofold suggesting that BRM down-
regulation may be significant for development and pro-
gression of GI cancers [77].
The reduction of BRM expression was observed in gas-
tric cancers, while in such cases, BRG1 level was unaf-
fected [78]. Importantly, this effect was characteristic 
only for cancer cells, but was not seen in premalignant 
lesions suggesting the importance of BRM loss at later 
stages of the stomach cancer development [79]. In about 
10% of gastric cancers, methylation of SMARCA2 pro-
moter region was identified [79].
Altered levels of BRM expression are also observed 
during pancreatic cancer development, although the 
mechanism is not yet fully understood. High levels of 
BRM are associated with patients’ poor survival, linked 
to larger tumour size, metastasis to other organs, lym-
phatic invasion and stage IV disease [80]. On the other 
hand, the downregulation of BRM may be a significant 
marker in the pancreatic cancer [57], indicating that 
BRM levels undergo dynamic changes in different stages 
of the disease. BRM silencing in pancreatic cancer cell 
line correlates with lower cell viability, proliferation rate 
and growth both in  vitro and in  vivo. This fact may be 
contrasted with the observation that downregulation of 
BRM is vital for pancreatic cancer progression [57] indi-
cating that BRM is actually essential for this process. 
Intriguingly, in data presented by Shain et  al., no pan-
creatic cancer cell lines with decreased BRM expression 
were observed [81]. A recent study indicated that BRM 
promotes pancreatic cancer growth and chemoresistance 
via activation JAK2/STAT3 pathway [57]. It also tran-
scriptionally regulates the miR-302a-3p and promotes 
pancreatic cancer metastasis by epigenetic modulation of 
SOCS5/STAT3 signalling axis [56]. However, to the large 
extent, the role of BRM in pancreatic cancer remains 
elusive.
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Hepatocellular cancer
According to current knowledge, normal human hepat-
ocytes display negative staining for BRG1 and positive 
for BRM protein [82]. The lack of BRG1 protein in nor-
mal human hepatocytes is, however, counterintuitive 
to expectations, especially given that in mouse models 
Brg1 is more important than Brm for liver regeneration 
after injury [28]. By contrast, a majority of hepatocellular 
carcinoma (HCC) is characterised by the positive BRG1 
staining. In 22.5% of HCC cases, the loss of BRM protein 
was found while in 15% of analysed cases both BRM and 
BRG1 were lost. The depletion of BRM in HCC signifi-
cantly corresponded to poor overall survival [82]. Pasic 
et al. correlated this phenomenon with the occurrence of 
BRM promoter polymorphisms that were also found in 
other cancers, leading to poorer patient survival [83].
Interestingly, in HCC tumour cells, additional cytoplas-
mic localisation of BRM was found, while no such cases 
were observed in healthy hepatocytes. This indicates that 
changes in BRM localisation may also contribute to car-
cinogenesis, although the mechanism of this phenom-
enon remains unknown [82].
Head and neck cancers
The head and neck squamous cell carcinoma (HNSCC) 
is one of the most common head and neck cancers, 
accounting for up to 90% of cases. In 16% of patient sam-
ples, the total loss of BRM was demonstrated, 11% fea-
tured weak staining and 16% were mosaic. Occurrence of 
SMARCA2 promoter region polymorphisms correlates 
with HNSCC risk, especially in HPV-positive oropharyn-
geal cancer [84].
In 5% of cases of salivary gland adenoid cystic carci-
noma (ACC), the SMARCA2 mutation was found [85]. 
Additionally, both mRNA and protein level of BRM 
were significantly elevated in ACC cells, comparing to 
the healthy tissue. Interestingly, the BRM overexpres-
sion was observed in every sample in all tumour areas, 
although ACC is the most heterogeneous cancer type. 
This strongly suggests that salivary gland ACC is charac-
terised by BRM overexpression [86] although the specific 
mechanism of BRM action in the ACC cells needs further 
elucidation.
Breast cancer
Cohet et  al. described that the presence of both SWI/
SNF ATPases is crucial for optimal cell cycle progression 
in non-malignant mammary epithelial cells and knock-
down of either BRM or BRG1 affects cell cycle, while 
the double knock-down of BRM and BRG1 results in cell 
death [87].
The analyses of a set of different breast cancers with 
various subtypes and stages revealed the increase of BRM 
levels in a significant majority of analysed cases [88]. 
However, the authors did not mention whether nuclear, 
cytoplasmic or other BRM staining was taken into con-
sideration. Additionally, it was observed that both BRG1 
and BRM are required for the triple-negative breast can-
cer (TNBC) proliferation and that double SMARCA2 and 
SMARCA4 knock-down results in slowed tumour growth 
in xenografts [88]. By contrast, a statistically significant 
downregulation of SMARCA2 transcript was observed 
in all breast cancer types comparing to healthy tissue. 
Based on this observation, it was postulated that expres-
sion of SMARCA2 and SMARCA4 has prognostic value 
[89], although another study shows that the BRM protein 
level varies among various breast cancer types. Namely, 
decreased level of BRM was observed in MDA-MB-231 
(TNBC cancer cell line) comparing to the less malignant 
MCF-7 (ER positive) cells. Furthermore, BRM regulates 
tight junction protein expression via targeting their pro-
moters, thus takes part in the breast cancer metastasis 
[90].
Gynaecological cancers
Although in gynaecological cancers many alterations of 
SWI/SNF subunits were observed [91–94], differences in 
BRM expression were found only in small cell carcinoma 
of the ovary, hypercalcaemic type (SCCOHT), ovarian 
cell carcinoma (OCC) and in the endometrial cancer.
SCCOHT is a rare subtype of the ovarian cancer that 
affects mainly young women. At first, loss of BRG1 
protein caused by somatic and germline mutations in 
SMARCA4 gene (coding for BRG1 protein) in SCCOHT 
was identified by a few groups [95–99]. Recently, loss 
of BRM protein was found in this type of cancer [100, 
101]. Importantly, no mutations in SMARCA2 gene were 
found, suggesting epigenetic control of SMARCA2 gene 
expression.
Noteworthy, for SCCOHT analysis, the ovarian clear 
cell carcinoma (OCCC), a different type of ovarian can-
cer, was used as a basis for comparison. Interestingly, in 
OCCC tumours, the lack of BRM or BRG1 was found 
but never loss of both ATPases. The mutations in the 
SMARCA2 gene, in about 2% of OCCC samples, were 
described [102]. Although, in epithelial ovarian cancer 
(the most common type of ovarian cancer) BRM overex-
pression strongly correlates with resistance to cisplatin, 
probably due to the reduction of apoptosis and influence 
of metabolism and cancer-associated signalling pathways 
[103]. These findings confirmed earlier discoveries that 
the downregulation of BRM increases cisplatin sensitiv-
ity [104].
The lack of both ATPases also was found in endome-
trial cancer [105], although no information about clinical 
significance of such loss has been so far described.
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Prostate cancer
Analysis of prostate cancer samples revealed that level 
of BRM was significantly downregulated in primary 
prostate tumours and metastases, although BRG1 level 
increased with the disease progression [106, 107]. The 
slightly lower signal for BRM was found in malignant 
sites comparing to the non-invasive parts of cancer [107]. 
BRM has been found to be required for the proliferation 
of AR-dependent prostatic adenocarcinoma cells [58].
Skin cancers
Alterations in BRM expression seem to be important for 
the non-melanoma skin cancer (NMSC) development, 
and in this case, the role of SMARCA2 as a susceptibility 
gene is strongly pronouncing. Analyses of NMSC patient 
samples, specifically squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC) with comparison to benign 
precancerous lesions—actinic keratosis (AK), which is 
claimed to be a progenitor for SCC and BCC develop-
ment, and normal skin showed that the transcript level of 
SMARCA2 gene decreased in SCC cells. By contrast, no 
differences were observed for SMARCA4 gene [108]. Sur-
prisingly, at the protein level, both BRM and BRG1 were 
downregulated about tenfold in both SCC and BCC com-
paring to AK and normal skin, indicating altered regula-
tion of their expression through some other mechanism. 
The authors suggested that loss of ATPases happens after 
the development of benign skin lesions, where no down-
regulation of BRM was observed [108]. Additionally, 
a mutation in SMARCA2 gene was identified in 17% of 
NMSC. Since this mutation was observed only in SCCs 
and BCCs and not in precancerous lesions or normal 
skin, this observation suggested that the mutation was 
preferentially selected in the process of cancer develop-
ment [109]. Subsequently, a possible mechanism underly-
ing BRM loss in NMSC was discovered based on a mouse 
model. It was found that mouse keratinocytes with 
deleted Brm (Brm−/−) grew faster than normal (Brm+/+) 
after UV-irradiation. This suggests the ability of Brm null 
mutant keratinocytes to escape UV-induced cell cycle 
arrest faster than in normal cells. Moreover, although 
Brm−/− keratinocytes accumulate more DNA damage, 
they do not compensate for this with more intense DNA 
repair [110]. All these effects result in the ability of Brm 
null mutant keratinocytes to undergo selective pressure 
that can cause overgrowth of cells with accumulated 
mutations over normal cells and hence lead to cancer 
development [110].
SWI/SNF ATPases are also claimed to be important 
components in regulation of microphthalmia-associated 
transcription factor (MITF) expression. MITF is a key 
factor linked to development of melanoma. BRG1 was 
described as a main epigenetic regulator of MITF expres-
sion. However, in case of cancers with inactivated BRG1, 
BRM replaces siblings ATPase and performs their func-
tion. In such cases, pharmacological exclusion of BRM 
could lead to the reduction of melanoma growth or even 
cancer cell death [111].
Other neoplasms
In case of leukaemia, evidence of the importance of BRM 
protein is rather weak. In this cancer type, SWI/SNF 
complexes are mainly built around the BRG1 ATPase 
that is essential for survival and growth of this neo-
plasm [112]. BRM is the main ATPase expressed in qui-
escent hematopoietic stem cells suggesting that loss of 
BRM significance takes place at the time of leukaemia 
development. This hypothesis is supported by discov-
ery of Doménech et  al. [113] who identified mutations 
in SMARCA2 gene in leukemic cells. In acute myeloid 
leukaemia with monosomy, 7 (about 13% of cases) novel 
mutations of SMARCA2 gene were identified, although 
these are not thought to be driving mutations because 
the samples were collected at more advanced stages of 
carcinogenesis [114]. In proximal-type epithelioid sar-
coma with pure rhabdoid tumour features, additional loss 
of BRM was found [115]. Additionally, the occurrence of 
SNPs in the SMARCA2 gene seems to correlate with risk 
for oligodendroglioma development [116].
Collectively, in various types of cancer, loss or strong 
decrease of BRG1 or BRM and sometimes both ATPases, 
was observed (Table  2). BRG1 and BRM seem to have 
similar/redundant function in cancer cells, although, 
they play different roles during human development. 
This hypothesis supports the observation that mutation 
in BRG1 encoding gene is frequently associated with 
CSS while the mutation in BRM-encoding gene is more 
typical for NCBRS. These two different genetic disorders 
carry some similar phenotypic aberration but also differ 
from each other (see Fig. 1). The exact role of BRM and 
BRG1 in somatic cells and how the imbalance in their 
abundance trigger to disorders or cancer development 
still remains unknown. Therefore, investigation of BRM 
and BRG1 differential function in various cancer types 
and in somatic cells seems to be one of the most exciting 
and important directions for further research.
Mechanism of BRM alteration in cancer
Alterations of BRM were reported in various cancer 
types, but only in some of them, SMARCA2 mutations 
were found. Therefore, it is highly probable that various 
mechanisms of BRM control exist including mutation-
independent regulation of SMARCA2 gene expression.
Page 10 of 17Jancewicz et al. Epigenetics & Chromatin           (2019) 12:68 
Mutations
In the majority of cancers lacking BRM, no mutations 
of the SMARCA2 gene were found suggesting that epi-
genetic regulation plays more crucial role in the BRM 
inactivation [82, 117, 118]. However, SMARCA2 muta-
tions were found in 78.2% of BRM-deficient ccRCC cases, 
although about half of them were silent [74]. All detected 
mutations were specific for cancerous tissue, especially 
low differentiated, and none or very low-level mutations 
were found in BRM-positive tissues as well as adjacent 
non-malignant tissues [74]. SMARCA2 gene mutations 
were also identified in about 10% of gastric cancers [79]. 
In NMSC, a mutation resulting in substitution of glu-
tamine by lysine was discovered. Interestingly, this muta-
tion type—G:C to T:A substitution is observed after 
UV-irradiation, what is a usual cause of skin cancer [109]. 
SMARCA2 mutations of unknown effect were also found 
in leukaemia [113].
Epigenetic modifications
Methylation of CpG sites on SMARCA2 promoter 
region is the key mechanism of BRM alterations [74]. It 
was recently found that Polycomb repressive complex 2 
(PRC2) causes epigenetic suppression of SMARCA2, by 
inducing H3K27me3 silencing pattern on its promoter 
region [119].
In BRM, deficient ccRCC methylation refers to over 
40% of cases and was found only in low-differentiated 
tumour areas [74]. A similarly observation was made in 
the AD of the lung, where SMARCA2 promoter meth-
ylation correlated with poor prognosis [40]. Nonetheless, 
in some cancers with lack/low BRM level, no mutations 
and no hypermethylation were found in the SMARCA2 
locus [108] suggesting the existence of other mechanisms 
involved in the control of BRM expression or protein 
stability.
Additionally, the activity of BRM is modulated by post-
translational modifications, for example acetylation can 
lead to BRM inactivation [120]. Three acetylation sites 
were identified in the BRM protein, although their spe-
cific functions remain elusive, and whether acetylation of 
only one or all sites is required for BRM inactivation is 
unknown [121].
Promoter insertion polymorphisms
Insertions in the promoter sequence of SMARCA2 gene 
(at positions −741 and −1321) was specified as silencing-
type polymorphism, leading to development of many 
Table 2 The alterations of BRM and BRG1 in various cancers
n/d—no data
a Upregulation of BRM in OCCC corresponds to resistance to cisplatin [103, 104]
Cancer type SMARCA2/BRM Refs. SMARCA4/BRG1 Refs.
Protein expression Genetic alterations Protein expression Genetic alterations
Rhabdoid tumours ↓ (concomitant INI1 
loss)
Epigenetic silencing [63, 121] ↓ Epigenetic silencing [121, 163–165]
Lung cancer ↓ Promoter polymor-
phism
[64–67] ↓/(loss) Mutations (LOF) [31, 64, 166, 167]
Renal cell carcinoma 
(RCC)
↓ Mutations [72–74] Concomitant loss 
with INI1 in rhab-
doid subtype
n/d [168]
Gastric cancer ↓ n/d [78, 79] Normal/↑ n/d [78, 169]
Pancreatic cancer ↑/↓ n/d [57, 80, 81] ↑? n/d [80]
Hepatocellular cancer ↓ Promoter polymor-
phism
[82, 83] ↑ n/d [82]
HNSCC ↓ n/d [84] n/d n/d –
ACC ↑ n/d [86] Normal n/d [86]
Oral cancer n/d n/d – ↑ Not determined [170]
Breast cancer ↑/↓ Not determined [88, 89] ↑ 2% [88, 171]
SCCOHT ↓(loss) n/d [100, 101] ↓/(loss) Somatic and germline 
mutations
[95–99]
OCCC ↓/↑a Mutations [102] n/d n/d –
Endometrial cancer ↓ Mutations [105] ↓ Mutations [105]
Prostate cancer ↓ n/d [106, 107] ↑ n/d [106, 107]
Melanoma n/d n/d – ↑ Rare mutations [172, 173]
NMSC ↓ Mutations [108] ↓ n/d [108]
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types of cancer [122]. Interestingly, the promoter inser-
tions cause HDACs recruitment and result in SMARCA2 
gene silencing [68]. Such insertions were associated with 
higher risk of lung cancer [68], colorectal cancer [76], and 
head and neck squamous cell carcinoma [84]. Increased 
risk of developing upper aerodigestive tract cancers 
appears only in case of double homozygous variants of 
such polymorphisms [77]. In the case of pancreatic can-
cer, the presence of SMARCA2 promoter polymorphisms 
is associated with poor prognosis for patients with diag-
nosed cancer rather than specific cancer risk [123].
Chromosomal aberrations
The loss of chromosome 9p, the SMARCA2 gene loca-
tion, results in BRM loss and enhanced cancer aggres-
siveness. In ccRCC aberrations of chromosome, 9p 
(monosomy or deletion) was found in over 40% of ana-
lysed BRM-deficient tumours [74]. Currently, the loss 
of 9p chromosome is used as a prognostic marker for 
ccRCC [124].
Moreover, loss of the BRM subunit may occur in cells 
with multiplication of chromosome 9. Multiple abnor-
malities also may lead to simultaneous silencing of all 
copies of the gene, e.g. by mutation and CpG methylation 
that occur in the same cancer cell [74].
BRM overexpression
Although a few malignancies with the upregulation of 
BRM were identified, a specific mechanism leading to 
BRM overexpression in neoplasms was not identified. 
In ACC samples, BRM was elevated on both protein and 
transcript level [86]. Overexpression of BRM correlated 
with poor survival and chemoresistance in pancreatic 
cancer. Similarly, in ovarian cancer, high level of BRM 
promoted resistance to cisplatin [80, 103].
New treatment strategies in BRM‑altered cancers
Only some malignancies with overexpression of BRM 
protein were identified, whilst in most of the neoplasms, 
the BRM is strongly downregulated or lost. The resto-
ration of BRM protein in BRM-deficient cancers leads 
to impeded cancer cell growth [63]. This effect may be 
obtained with chemical compounds. Thus, the search of 
such compounds is encouraged [118, 125].
The first study considering direct BRM targeting was 
development of selective SMARCA2/4 bromodomain 
inhibitor (PFI-3), although PFI-3 did not reveal anti-
proliferative effect in cancer cells. This observation 
indicated that bromodomain is not a proper therapeu-
tic target, and research focused on targeting helicase/
ATPase domain in BRM for synthetic-lethality ther-
apy [126]. Recently, small molecules for inhibition 
of BRM and BRG1 ATPase activity were discovered. 
In a BRG1-deficient lung cancer xenograft model, 
these inhibitors downregulated BRM-dependent gene 
expression and exhibited antiproliferative effect upon 
oral administration [127]. Another approach based 
on proteolysis-targeting chimera (PROTAC) has been 
designed to target BRM/BRG1 subunits of SWI/SNF 
CRCs employing a bromodomain ligand to recruit the 
VHL, the E3 ubiquitin ligase facilitating protein degra-
dation [128].
Polymorphisms in SMARCA2 gene in position −747 
and −1321 are suggested to be responsible for HDAC 
recruitment, and HDAC inhibitors (HDACi) cause 
upregulation of both BRM transcript and protein lev-
els in cell lines [26, 100, 120, 129, 130]. Application 
of HDACi in patient groups seems to be a promising 
therapy, especially now as HDACi are approved by 
Food and Drug Administration and European Medi-
cines Agency, and are becoming a more popular choice 
of treatment in various types of human cancer [131]. A 
similar effect on BRM expression was obtained during 
flavopiridol (synthetic flavonoid) treatment of rhabdoid 
cell lines [63]. Importantly, some studies demonstrated 
that whilst utilisation of HDACi effectively induces 
BRM, it also leads to an increase of BRM acetylation 
which impairs its function, giving no therapeutic effect 
overall [120].
In tumours with SMARCA2 depletion caused by 
PRC2-driven methylation, usage of EZH2 inhibi-
tors seems to be a promising therapy. Effectiveness of 
this kind of drug was demonstrated for ovarian can-
cer (SCCOHT) in in  vitro models [132]. Interestingly, 
in SCCOHT, a synergistic effect was observed, when 
EZH2 inhibitors were used together with HDACi [133]. 
Unfortunately, such an approach appeared to be not 
suitable for every type of cancer with BRM depletion: 
for instance, in lung cancer cell lines and pancreatic 
cancer cell lines, no therapeutic effect was observed.
BRM appeared as an attractive therapeutic target 
and induction of its activity may be helpful in cancer 
treatment. Therefore, a special reporter system was 
designed to identify novel compounds that restore 
not only BRM protein level, but also its function, giv-
ing hope for effective epigenetically focused treatment 
[125].
BRM and BRG1 are mutually exclusive ATPase 
subunits of SWI/SNF CRCs. Therefore, BRM target-
ing in BRG1-deficient cancer is expected to cause syn-
thetic lethality [134]. So far, this phenomenon has been 
described for lung and ovarian cancers [126, 127, 135].
Possibilities for incorporation of BRM/SMARCA2-
related targeted therapy into the clinic are still developing 
and new strategies seems to be very promising and effec-
tive (Fig. 4).
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Conclusions
BRM deficiency or downregulation was found in various 
types of cancer, although its function in cancer develop-
ment and progression remains elusive. Interestingly, the 
mutation rate in SMARCA2 gene is quite rare compared 
to mutations in SMARCA4, suggesting a less impor-
tant role of BRM ATPase containing SWI/SNF CRCs in 
carcinogenesis. Some data indicated SMARCA2/BRM 
as a tumour suppressor or tumour susceptibility gene, 
whereas overexpression of BRM caused cancer resistance 
for chemotherapy leading to cancer progression indicat-
ing its promoting role. All available data concerning BRM 
in cancer suggest that BRM function differs depend-
ing on cancer type. Thus, BRM acts in some cases as a 
tumour suppressor and in other cancer types or stages as 
a tumour or disease-promoting factor. Moreover, in some 
tumour types, loss or downregulation of BRM occurs 
during cancer development in late stage or in poorly 
differentiated/undifferentiated cancer cells suggesting 
clonal selection of BRM-deficient cancer cells. Addition-
ally, some SMARCA2 missense mutations result not only 
in BRM loss of function but also may lead to production 
of gain-of-function BRM protein, likely influencing the 
whole BRM containing SWI/SNF CRC’s activity.
Based on ample recently published data, BRM seems 
to be a perfect target for various anticancer therapies 
including ATPase activity inhibition, synthetic lethal-
ity induction, etc. However, in view of current knowl-
edge, i.e. given the high similarity of the ATPase domain 
among various proteins involved in the control of numer-
ous regulatory processes, such optimism should be mod-
erated by the risk of severe side effects of such therapies 
through off-target effects. During designing of the BRM-
based anticancer therapy, another important fact needs 
to be urgently taken into consideration, namely, the 
observation that normal hepatocytes are negative for 
BRG1 ATPase. In such case, any BRM-targeting small 
molecule drugs can cause severe and unexpected nega-
tive effects on liver activity which may be impossible to 
detect during initial tests on cancer lines or in mice, as 
in this model, Brm seems to have a diverse function than 
in human liver. The damaging effect of BRM-targeting 
compounds likely may be observed in any tissue charac-
terised by the lack of BRG1 protein. Therefore, additional 
study on BRM function in normal tissues and cancers is 
clearly required for better understanding of the interde-
pendence between both ATPases, to precisely and safely 
treat cancer patients with new anti-BRM compounds or 
compound-based therapies.
Another important issue in the study of BRM func-
tion in development and carcinogenesis is the alter-
native splicing of SMARCA2 gene, which is relatively 
unexplored. According to the NCBI database, there are 
seven alternative transcripts of SMARCA2 gene. A simi-
lar situation is observed in mice, where six alternative 
transcripts exist. There are no data about the tissue or 
developmental stage-specific expression of these splic-
ing variants either in mice or in humans. The relevance of 
BRM alternative splice variants in cancer is overlooked, 
although such a multiplicity of alternative BRM splicing 
variants suggests far more potential regulatory or patho-
logical functions of the BRM protein which may be spe-
cific for certain cancer types or developmental stages. 
Knowledge about the existence of truncated BRM forms 
in cancer is very limited, although it is very likely that 
such incomplete but still partially functional proteins 
are produced due to unusual splicing events frequently 
occurring in various cancers. Such truncated BRM forms 
may have a very strong negative or gain-of-function effect 
on the functionality of the whole SWI/SNF complex, and 
thus may lead to the de-regulation of numerous impor-
tant regulatory cellular processes fine-tuned by SWI/SNF 
complexes.
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Fig. 4 Cancer treatment related to BRM protein. Ideas for utilising 
BRM in anticancer therapy are emerging. Such therapies, taken 
currently into consideration, are based on BRM level restoration 
by, e.g. HDAC inhibitors and E2F inhibitors. A very promising but 
demanding idea is based on a synthetic lethality approach, targeted 
against BRM ATPase domain or bromodomain
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